Clinical Trial Update: Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial of ispinesib in young patients with relapsed or refractory solid tumors and lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Burkitt Lymphoma
• Childhood Central Nervous System Germ Cell Tumor
• Childhood Choroid Plexus Tumor
• Childhood Craniopharyngioma
• Childhood Grade Ii Meningioma
• Childhood Grade Iii Meningioma
• Childhood Grade Meningioma
• Childhood High-grade Cerebral Astrocytoma

Drugs mentioned

• Ispinesib (ispinesib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Status: COMPLETED